USP Labeling Standards Highlight Patient Safety - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

USP Labeling Standards Highlight Patient Safety

Labeling standards for ferrules and cap overseals that focus on the warnings necessary to prevent imminent life-threatening situations became official on Dec. 1, 2013, the US Pharmacopeial Convention (USP) announced in a press release.

The standards explicitly state that warning messages, such as “Warning—Paralyzing Agent” or “Dilute Before Using,” are the only markings that should appear on ferrules and cap overseals subject to USP General Chapter <1> Injections, providing an additional layer of protection for healthcare practitioners prior to administering an injectable drug to a patient. Under the standards, if a nurse, physician, or pharmacist sees a warning on a ferrule or cap overseal, he or she will know immediately that it is a vital, possibly life-saving piece of information that must be observed and acted upon before administering the drug to the patient.

The standard indicates that ferrules and cap overseals must remain clear of any markings, including logos, except those intended to prevent an imminent life-threatening situation. Products that do not require cautionary statements should be free of information, so that those with cautionary statements are immediately apparent. The standards also require that such warnings be printed in a contrasting color and be clearly visible under ordinary conditions of use. Other requirements include restricting the location of information that is important but less urgent to be located elsewhere on the vial. This would include, for example, lot numbers, product or company names, and logos. If no urgent warning is necessary, the top surface must remain blank to help ensure that urgent warnings on other injectable medications are readily noticed.

The standards are the result of careful reviews and consultation between USP and medical, nursing, and pharmacy practitioners; FDA; and other stakeholders. They were first published in the 2011 National Formulary (USP–NF), with a delayed official date of Dec. 1, 2013 to allow manufacturers time to comply with the standard.

While these labeling standards for ferrules and cap overseals became official in General Chapter <1> Injections in USP–NF, the location of the standard will shift to General Chapter <7> Labeling, which is intended to be made applicable to all articles in USP-NF.  This new general chapter has been proposed in the November–December 2013 issue of Pharmacopeial Forum and provides definitions and standards for labeling of official articles. The official date of the section currently in General Chapter <1> on Labeling of Ferrules and Cap Overseals is not affected by the proposed General Chapter <7>, which has a comment deadline of Jan. 31, 2014.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here